GlassScriptPhysician profile
Jennifer Evans
NPI 1063781532
$2,799.72
in general payments reported to CMS, 2019-2025
17 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $1,166 · 2023: $680 · 2024: $185 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.34 | 2021-2025 | |
| Alkermes, INC. | $451.39 | 2021-2024 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $271.60 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $233.53 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.17 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $176.50 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.64 | 2024-2025 | Cobenfy |
| Corium, LLC | $101.15 | 2023-2025 | Azstarys |
| Indivior INC. | $61.79 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $50.41 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $33.99 | 2021-2023 | Trintellix |
| Almatica Pharma LLC | $30.24 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Novartis Pharmaceuticals Corporation | $24.01 | 2022 | |
| Sanofi Pasteur INC. | $22.14 | 2021 | |
| Lundbeck LLC | $18.33 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $15.18 | 2023 | Inpefa |
| Idorsia Pharmaceuticals US INC | $13.31 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.